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G E N E T I C S
Guide-free Cas9 from pathogenic Campylobacter jejuni 
bacteria causes severe damage to DNA
Chinmoy Saha1*, Prarthana Mohanraju2*, Andrew Stubbs3, Gaurav Dugar4†, Youri Hoogstrate3, 
Gert-Jan Kremers5, Wiggert A. van Cappellen5, Deborah Horst-Kreft1, Charlie Laffeber6,  
Joyce H.G. Lebbink6,7, Serena Bruens6, Duncan Gaskin8, Dior Beerens1‡, Maarten Klunder2§, 
Rob Joosten2, Jeroen A. A. Demmers9, Dik van Gent6, Johan W. Mouton1||, Peter J. van der Spek3¶, 
John van der Oost2¶, Peter van Baarlen10, Rogier Louwen1¶
CRISPR-Cas9 systems are enriched in human pathogenic bacteria and have been linked to cytotoxicity by an 
unknown mechanism. Here, we show that upon infection of human cells, Campylobacter jejuni secretes its Cas9 
(CjeCas9) nuclease into their cytoplasm. Next, a native nuclear localization signal enables CjeCas9 nuclear entry, 
where it catalyzes metal-dependent nonspecific DNA cleavage leading to cell death. Compared to CjeCas9, native 
Cas9 of Streptococcus pyogenes (SpyCas9) is more suitable for guide-dependent editing. However, in human cells, 
native SpyCas9 may still cause some DNA damage, most likely because of its ssDNA cleavage activity. This side 
effect can be completely prevented by saturation of SpyCas9 with an appropriate guide RNA, which is only partially 
effective for CjeCas9. We conclude that CjeCas9 plays an active role in attacking human cells rather than in 
viral defense. Moreover, these unique catalytic features may therefore make CjeCas9 less suitable for genome 
editing applications.
INTRODUCTION
CRISPR-Cas is an RNA-guided adaptive defense system that enables 
prokaryotes to recognize and destroy the nucleic acids of invading 
genetic elements (i.e., viruses or plasmids) by Cas nucleases (1). 
Besides providing adaptive immunity, CRISPR-Cas systems have been 
demonstrated to play a role in other processes (2), including bacterial 
pathogenicity (3). Comparative genomic analysis demonstrated high 
prevalence of type II CRISPR-Cas systems, characterized by the 
presence of the Cas9 gene, in bacterial pathogens (4). In the pathogens, 
such as Francisella novicida, Neisseria meningitidis, and Campylobacter 
jejuni, Cas9 activity was found to correlate with the death of infected 
human cells (5, 6) or infected laboratory animals (6).
The Cas9-encoding operons in strains of C. jejuni typically con-
tain small or degenerated CRISPR arrays (fig. S1A) (7), which play 
only a minor role, at most, in viral defense (5). One of the proposed 
roles for type II CRISPR-Cas system in pathogenicity is the Cas9- 
mediated silencing of the expression of genes encoding exposed cell 
wall lipoproteins through an antisense mechanism; infectious bacteria 
have effectively used this strategy to evade the human immune system 
(8). Another important phenomenon is the capacity of several intra-
cellular bacterial pathogens that harbor Cas9, including C. jejuni, to 
induce double-strand DNA breaks (DSBs) in infected human host 
cells, either actively by secreted bacterial cytotoxins or passively 
by activating the host’s cell death responses (9). Multiple cytotoxins 
have been identified in C. jejuni, such as the cytolethal distending 
toxin (CDT), a bacterial toxin that induces host DNA damage (10). 
However, CDT lacking C. jejuni isolates still induce DNA damage 
(11), and campylobacteriosis (12, 13) indicated that an additional 
factor is involved in the induction of DNA damage and eukaryotic 
cell death. Previously, we reported on the role of CRISPR-Cas9 system 
in C. jejuni virulence and disease severity and revealed that damage 
induced upon human cells in cellular infection assays correlated with 
the presence of C. jejuni Cas9 (CjeCas9) (5); others have reported 
that cas9 was differentially expressed during C. jejuni passage across the 
mouse intestine (14). However, the molecular mechanism responsible 
for the observed CjCas9-related cytotoxicity remained elusive (5). Here, 
we show that upon the release of the CjeCas9 nuclease, C. jejuni 
induces DNA damage that leads to human cell death.
RESULTS AND DISCUSSION
CjeCas9 is secreted via OMVs into human cells
First, to validate our previous work (5), we corroborated by comple-
mentation a role for CjeCas9 in cytotoxicity (fig. S1, B and C). We 
then explored how C. jejuni releases the 984–amino acid protein 
CjeCas9 to unleash its toxic effect on human cells. Some studies 
support the notion that cytotoxins are secreted either by dedicated 
export systems (9) or by outer membrane vesicles (OMVs) (15). 
The pathogenic C. jejuni reference isolate NCTC11168 produces 
OMVs (15, 16) that contain CjeCas9, as identified by a proteomic 
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analyses (16). We therefore investigated whether CjeCas9 is present 
in the OMVs of our C. jejuni model strain GB11, a strain genetically 
highly similar to the isolate NCTC11168 (17). First, we made a 
CjeCas9-mCherry variant in our model strain by fusing the cas9 
gene to the mCherry gene from which a red fluorescent protein is 
produced to track CjeCas9 in human cells after being released from 
the C. jejuni OMVs. Subsequently, after isolation of the OMVs, 
produced and secreted by our model strain and the reference isolate 
NCTC11168, CjeCas9 or CjeCas9-mCherry were both detected on 
a Western blot containing the OMV lysates (fig. S2A). We then per-
formed bacterial infection experiments to study the release of 
CjeCas9-mCherry by C. jejuni into human cells. By fluorescence 
microscopy, we observed that CjeCas9-mCherry accumulated in 
the cytoplasm and the nucleus (Fig. 1A and fig. S2B). As C. jejuni 
infections of human cells are accompanied by severe DNA damage 
(18), we speculated that the observed nuclear localization and the 
nuclease activity of CjeCas9 (19) could play a direct role in the 
pathogenicity of C. jejuni (fig. S2, C and D), including the induction 
of DNA damage (fig. S2E).
CjeCas9 nuclear entrance of human cells is facilitated by 
an autonomous nuclear localization signal
The observed nuclear localization of native CjeCas9, produced by 
C. jejuni bacteria during their infection of human cells, indicated 
that CjeCas9 was able to enter the nuclei of human cells without 
prior addition of a synthetic nuclear localization sequence (NLS). 
To assay for the autonomous nuclear entry of CjeCas9, we fused the 
genes that code for CjeCas9 and enhanced green fluorescent protein 
(eGFP) into a eukaryotic expression vector. After the transfection of 
the recombinant expression vectors into human cells, we observed 
nuclear eGFP-CjeCas9 accumulation by fluorescence microscopy 
(Fig. 1B and fig. S3A) and a Western blot analysis (Fig. 1C). In silico 
analysis of the GB11 CjeCas9 protein sequence predicted a potential 
NLS in the Cas9 arginine-rich bridging helix (BH) (20) region (fig. S3B), 
which plays an important role in guide RNA binding (21). The predicted 
NLS in CjeCas9 shares extensive sequence identity with arginine-rich 
domain sequences that occur in the viral dual-function proteins 
that enable RNA binding and nuclear localization (22, 23). To assess 
whether the predicted CjeCas9 NLS facilitated nuclear entry, the 
DNA fragment encoding the CjeCas9 NLS region was fused to the 
egfp gene in the same eukaryotic expression vector, as described 
above. After the transfection of human cells, correctly expressed 
eGFP-NLS (CjeCas9) accumulated in the nucleus, almost as effi-
ciently as eGFP fused to the well-established NLS of Simian virus 
(SV) 40 large T antigen protein (fig. S3C). Deletion of the NLS region 
in CjeCas9 disabled its accumulation into the nucleus (fig. S3D), 
validating the relevance of the NLS region for the nuclear entry 
of CjeCas9.
CjeCas9 induces DNA damage in human cells
The observed nuclear localization, together with the established endo-
nuclease activity of CjeCas9 (19), led us to hypothesize that CjeCas9 
produced and released by C. jejuni during infection of human cells 
could potentially alter DNA integrity and cell homeostasis. This idea 
originated from two studies that revealed that Cas9-mediated DSBs 
induced a p53-mediated DNA damage response in human cells, a 
phenomenon that may also lead to cell death (24, 25). We used 
antibody staining to investigate whether the p53-binding protein 1 
(53BP1), an important regulator of the cellular response during DSB 
repair (26), is activated in human cells upon infection with C. jejuni 
bacteria. Six hours after infection, the microscopic analysis revealed 
significantly increased numbers of 53BP1 foci in the nuclei of human 
cells that were infected with either Cas9-producing wild-type (WT) 
GB11 or a complemented GB11cas9::cas9 (cas9::cas9) C. jejuni 
Fig. 1. CjeCas9 is released by C. jejuni during infection of human cells and translocate into their nuclei. (A) Representative microscopic images of human cells 
infected with C. jejuni bacteria (anti–C. jejuni FITC, green) expressing Cas9-mCherry (red). FITC is fluorescein isothiocyanate, a green fluorescent tracer. (B) Representative 
microscopic images of nuclear eGFP (enhanced green fluorescent protein)–CjeCas9 localization in human cells (green). The eGFP transfected cells represent a control. 
(A and B) Nuclei are counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (C) Nuclear (NP) and cytoplasmic (CP) protein fractions of human cells. Glyceraldehyde 
phosphate dehydrogenase (GAPDH) verified the quality of the separation.
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bacteria but not in the cells infected with the corresponding cas9 
deletion mutant, GB11cas9 (cas9) (Fig. 2, A and B). This obser-
vation was validated in infection assays similar to those above but 
now by using the phosphorylated histone H2A variant X (-H2AX), a 
well-established histological marker of DSB-associated chromatin 
decondensation (27). Upon infection by CjeCas9-producing bacteria 
(WT or cas9::cas9) (Fig. 2, C and D, and fig. S4, A to C) or exposure 
to the OMVs produced by these bacteria (fig. S4, D and E), human 
cells displayed bright red nuclei after fluorescent antibody staining of 
-H2AX. Compared to human cells infected with CjeCas9-producing 
bacteria, significantly fewer -H2AX–positive bright red nuclei or 
activated 53BP1-positive foci were observed in human cells infected 
with the cas9 bacteria (Fig. 2, A to D, and fig. S4, A, C, and F) or 
when exposed to their OMVs (fig. S4, D and E). Although infection 
efficiencies of C. jejuni isolates may differ substantially (fig. S4G) 
(5), the significantly reduced activation of 53BP1 and -H2AX in hu-
man cells challenged with cas9 bacteria cannot be simply explained 
by their lower infection efficiency. We observed a factor 1000 in-
crease in invasion numbers for GB11 compared to NCTC11168 
bacteria, whereas the overall CjeCas9-induced cytotoxicity (5) and 
DNA damage, as measured by 53BP1 and -H2AX, was equal 
(Fig. 2, A to D, and fig. S4, A and C to F). Together, this suggests 
that the cytotoxicity of C. jejuni strains may not be substantially 
influenced by adhesion and invasion but more by the secretion 
of differential CjeCas9 variants (5, 7), the relative abundances of 
Cas9 in OMVs, the amounts of OMVs secreted by a strain, and the 
amounts of human cells that are targeted by OMVs released by the 
corresponding strain.
Comparative genomics indicated that C. jejuni strains produce 
varying numbers of virulence factors (28, 29). However, to date, only 
CDT has been shown to damage DNA (9). CjeCas9 is a nuclease that 
cleaves double-stranded DNA (dsDNA) (19, 30), but its potential role 
to induce DNA damage during infection has not yet been studied. 
To discriminate between the activities of CDT and Cas9, infection 
studies as described above were performed using two C. jejuni strains 
that both expressed CjeCas9 but produced or lacked CDT. By analyzing 
the DNA integrity and cell homeostasis as above, it was revealed 
that human cells infected with either producing or nonproducing 
CDT C. jejuni bacteria, of which the latter also lacked cas1, cas2, and 
CRISPR RNAs (crRNAs), displayed the same degree of activation of 
Fig. 2. CjeCas9 activates the chromatin and DNA integrity markers, 53BP1 and -H2AX, in U2OS cells. C. jejuni GB11 (WT) and its variants cas9 or cas9::cas9 were 
stained with anti–C. jejuni FITC (green), and nuclei were counterstained with DAPI (blue). Gamma ()–irradiated cells are used as a positive control, and untreated cells 
were used as a negative control. (A) Representative microscopic images of human cells infected with WT, cas9, or cas9::cas9 were stained for 53BP1 (red). (B) The 
number of 53BP1 related foci per cell (mean foci per cell, y axis) were counted in human cells. The C. jejuni bacteria used are shown on the x axis. (C) Representative 
microscopic images of human cells infected with WT, cas9, or cas9::cas9 were stained for -H2AX (red). (D) The percentage of human cells with bright red nuclei is 
displayed on the y axis. The C. jejuni bacteria used are listed at the x axis. Values represent means ± SEM. ***P < 0.001 [one-way analysis of variance (ANOVA), Bonferroni’s 
multiple comparison test].
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-H2AX and 53BP1 (fig. S5, A to C). These results corroborated 
previous studies, demonstrating that CDT is not the sole factor 
responsible for disrupting chromatin and DNA integrity during 
human cell infection by C. jejuni (11, 31).
To examine whether, specifically, the CjeCas9 nuclease activity 
leads to disruptions in human cellular chromatin and DNA integrity, 
we quantified -H2AX–stained nuclei in human cells that were 
transduced with plasmids encoding either eGFP-CjeCas9 or its 
catalytically inactive (dead) variant, eGFP-CjedCas9 [introduction 
of a single-nucleotide polymorphism (SNP) in cjecas9 could be 
more accurately controlled and validated in plasmids than in the 
C. jejuni genome]. At comparable transfection efficiencies (fig. S6, 
A and B), significantly elevated frequencies of -H2AX–positive nuclei 
were detected in human cells transfected with eGFP- CjeCas9 as com-
pared to cells transfected with eGFP-CjedCas9 (fig. S6C). These 
results were further validated by Western blot analysis of -H2AX 
in lysates generated from transfected eukaryotic cells (fig. S6D). The 
53BP1, -H2AX immunohistochemistry, and -H2AX Western blot-
ting results thus support the notion that CjeCas9 catalytic nuclease 
activity alters human chromatin and DNA integrity.
CjeCas9 is associated with the induction of DSBs
The BLESS (direct in situ breaks labelling, enrichment on streptavidin 
and next-generation sequencing) method (32) was used during infec-
tion experiments with Cas9-producing and nonproducing strains 
to obtain a genome-wide snapshot impression profile of DNA DSB 
induction correlating with CjeCas9 activity. The BLESS analysis 
(Fig. 3A) revealed that human cells infected for 6 hours with WT or 
cas9::cas9 bacteria harbored substantial numbers of DSBs (Fig. 3B, and 
fig. S7, A and B), of which 678,910 (WT) or 942,104 (cas9::cas9) 
were CjeCas9 dependent (table S1). Note that numbers of unique 
Cas9-dependent DSBs were obtained after background correction, 
i.e., subtraction of DSBs obtained by BLESS from uninfected 
(93,373) or cas9 bacteria–infected (190,111) human cells incubated 
in parallel (table S1). The BLESS data thus showed that production 
of native CjeCas9 correlated with increased numbers of DSBs in nuclei 
of infected human cells (Fig. 3B and fig. S7, A to D), consistent with 
our data on 53BP1 and -H2AX activation. The three reported CjeCas9 
protospacer adjacent motifs (PAMs) (19, 33, 34) were not enriched 
adjacent to the detected DSBs (Fig. 3C and table S2), indicating that 
the processing of human cellular DNA by native CjeCas9 during 
infection by C. jejuni is PAM independent.
RNA-independent genomic DNA cleavage by CjeCas9
Our finding that CjeCas9 could be cleaving PAM independently is 
in line with a recent analyses describing that Cas9 proteins obtained 
from Streptococcus pyogenes (SpyCas9) and F. novicida (FnoCas9) 
cleave plasmid DNA in a PAM- and RNA-independent manner 
(35). In the absence of a guide RNA, SpyCas9 (type II-A) cleaves 
single-stranded DNA (ssDNA), while FnoCas9 (type II-B) nicks 
plasmid dsDNA (35). These RNA-independent activities are dependent 
on Mg2+/Mn2+ cations and require the RuvC domain of SpyCas9 
and the HNH domain of FnoCas9 (35). We considered that these 
metal ions most likely play an important role in the PAM- and 
RNA-independent DNA processing activity of CjeCas9. Plasmid 
cleavage experiments in the presence of Mg2+ using purified recombinant 
Fig. 3. Analysis of chromosomal DSBs induction using BLESS. (A) Overview illustration of the BLESS method after C. jejuni infection of U2OS cells. (B) Histogram show-
ing numbers of DSBs accumulated during bacterial infection. Cells that were 1 Gy (gray) irradiated are used as a positive control. Untreated cells were used as a control in 
the BLESS analyses. (C) Example outcome of PAM analyses. y axis shows the percentage of the 5′-NNNVRYM-3′ PAM motif that is detected in the BLESS-obtained DSBs 
breaks, as observed in raw and filtered datasets obtained from the samples shown on the x axis.
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Fig. 4. In vitro cleavage assay and in vivo genome editing efficiencies of native CjeCas9 and SpyCas9 in human cells. (A) CjeCas9 activity and the effect of divalent 
cations (Mn2+ and Mg2+) concentration on plasmid DNA cleavage. SC is super coiled, L is linear, and OC is open-circle plasmid DNA. (B) Restoration of GFP expression 
mediated by CjeCas9 or SpyCas9 genome editing in human cells [K562(GFPmut)] and quantified using FACS. In Q1-LR, the percentages of CjeCas9 or SpyCas9 genome 
edited cells that have a restored GFP expression are visualized (green). Q1-UL are dead cells. Q1-UR are GFP-positive dead cells. Q1-LL are unedited [K562(GFPmut)] cells. 
(C and D) Percentages of apoptotic human cells (K562) obtained after 6 hours. Concentration of CjeCas9 or SpyCas9 is 30 pmol, and for the sgRNA, the concentrations are 
30, 60, and 90 pmol [for single guide RNA1 (sgRNA1), sgRNA2, and sgRNA3, respectively]. Results shown as means ± SEM. ***P < 0.001 and **P < 0.01 (one-way ANOVA, 
Bonferroni’s multiple comparison test).
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CjeCas9 and SpyCas9 proteins (fig. S8A) showed that activity of these 
nucleases was Mg2+ dependent (fig. S8B). Guide-free CjeCas9- 
induced DSBs in the presence of at least 2 mM Mn2+ or nicks at 
500 M Mg2+ or 100 M Mn2+ in plasmid dsDNA (Fig. 4A). Notably, 
C. jejuni infects mainly the intestinal epithelial cells of the jejunum 
(36), where the highest concentrations of the divalent cations manganese 
and magnesium can be found. Physiological ranges for turnover of 
manganese are in an adult 0.9 to 10 mg/day (37), for magnesium this 
is about 300 mg/day (38); the jejunum also adsorbs 125 mM/day 
magnesium (39). Noteworthy, manganese is crucial for pathogens 
to colonize and attack the host, with specific systems being activated 
to fight for this crucial metal ion uptake (40). The tested Mn2+ and 
Mg2+ metal ion concentrations used in the in vitro CjeCas9 assays 
are thus of biological relevance. Under the same experimental con-
ditions, SpyCas9 did not cleave dsDNA (fig. S9A), but it did cleave 
ssDNA (fig. S9B), reproducing findings from a different study (35). 
To identify whether the divalent cation-dependent cleavage of plas-
mid dsDNA by CjeCas9 was catalyzed by the RuvC or HNH domain, 
we carried out the same metal ion–dependent cleavage assays with 
WT, as well as RuvC and/or HNH active site mutants of CjeCas9. We 
found that the guide-independent activity of CjeCas9 that cleaves 
plasmid dsDNA was completely abolished in both the HNH- inactive 
single mutant and the HNH/RuvC-inactive double mutant (Fig. 4A 
and fig. 9C). This shows that the guide-independent processing of 
double-stranded plasmid DNA depends on the activity of the CjeCas9 
HNH domain in the presence of Mn2+ or Mg2+. When CjeCas9 or its 
active site–mutated variants were incubated together with human 
chromosomal DNA isolated from U2OS cells, CjeCas9 with a func-
tional HNH domain and Mn2+ or Mg2+ cations were sufficient to com-
pletely degrade human genomic DNA (fig. S10, A and B), confirming 
the results obtained with the plasmid DNA. This finding was vali-
dated by staining for -H2AX on a Western blot containing eukaryotic cell 
lysates generated from human cells transfected with eukaryotic expres-
sion vectors that enabled the expression of CjeCas9, CjeCas9RuvC, 
CjeCas9HNH, or the dead variant CjedCas9 (fig. S10C).
The RNA guide-independent processing of double-stranded 
human DNA by CjeCas9 that we observed is very different from the 
reported guide-dependent targeting activity by SpyCas9, the most 
frequently used enzyme in genome editing applications (41). We 
tested the extent to which the features observed for CjeCas9 also 
apply to SpyCas9. First, we fused eGFP to full-length SpyCas9 or its 
arginine-rich BH motif and cloned them into a eukaryotic expression 
vector, after which the two different vectors were transfected into 
human cells. Fluorescence microscopy (fig. S11, A and B) and Western blot 
analysis of the cytoplasmic and nuclear fractions (fig. S11C) revealed 
that eGFP-SpyCas9 does not require an exogenously introduced NLS 
to reach the nucleus. Next, GFP-SpyCas9 activated -H2AX, indicating 
that DNA integrity had been altered (fig. S12, A and B), as observed for 
GFP-CjeCas9. In vitro incubations of chromosomal DNA and SpyCas9 
indicated that SpyCas9 does not cleave dsDNA (fig. S12C), whereas 
CjeCas9 does (fig. S10B). However, in human cells, guide-free SpyCas9 
alters DNA integrity as measured by -H2AX activation (fig. S12D). 
This likely relates to the guide-free activity of SpyCas9 targeting ssD-
NA on transiently exposed regions of the chromosomes (fig. S9B).
Comparing genome editing efficiencies between native 
CjeCas9 and SpyCas9
We then used an established procedure to compare genome editing 
efficiencies of native CjeCas9 and SpyCas9 in human cells. Briefly, 
native Cas9 proteins together with a gfp-targeting RNA guide and a 
homologous gfp-repair template were introduced by lipofection 
into human cells to restore a mutated gfp gene in the genomic 
AAVS1 locus; successful editing events result in restored GFP 
production that can be quantified by fluorescence-activated cell 
sorting (FACS) analysis (42). We found that genome editing by CjeCas9 
was at least 100 times less efficient than by SpyCas9 (Fig. 4B and fig. S13, 
A to D), which, in part, may be because of the poor helicase activity 
of this enzyme (43). We noticed differences in the number of dead 
cells when comparing guide-free Cas9 nucleases with Cas9 nucleases 
saturated with a guide RNA during genome editing procedures. 
Dedicated analyses using SpyCas9 and CjeCas9 revealed that satura-
tion of native SpyCas9 proteins with a nontargeting guide RNA 
reduced numbers of death cells to background levels (Fig. 4C), 
whereas saturation of CjeCas9 proteins with a nontargeting guide 
RNA only slightly reduced the numbers of dead cells (Fig. 4D). This 
difference could relate to the reduced binding strength of guide 
RNAs to the relatively small CjeCas9 protein (43).
In conclusion, we demonstrate here that Cas9 proteins can 
autonomously translocate into the nucleus of human cells. In here, 
Mn2+- or Mg2+-dependent DNA processing by guide-free Cas9 proteins 
occurs nonspecifically, and dsDNA nicking and DSB induction 
activities of CjeCas9 may lead to substantial genomic DNA damage 
that may overwhelm human cells and prohibit their survival. Metal 
ion–dependent and RNA-independent CjeCas9 activity provides a 
clear mechanistic explanation for the cytotoxicity to human cells we 
previously observed in C. jejuni infection experiments using human 
cells (5). We propose a working model on the role of CjeCas9  in 
bacterial-induced cytotoxicity (fig. S14). Overall, we conclude that 
CjeCas9 has the potential to actively participate in the attack of human 
cells rather than in the defense against viruses. Moreover, the 
unique catalytic features of CjeCas9 may therefore make this nucle-
ase less suitable for genome editing applications.
MATERIALS AND METHODS
Bacterial strains and growth conditions
The C. jejuni isolates used in this work harbor a type II-C CRISPR-Cas 
system, but GB11 lacks a CRISPR array (5, 17) and the C. jejuni (cdt-) 
strain only harbors cas9 (fig. S1A). All the used strains are listed 
together with their generated cas9 variants in table S3. The methods 
for generating cas9 and growth conditions have been described 
previously (5). The same method was used for generating the cas9::cas9 
as for generating cas9 (5), with the exception that not cas9 was 
disrupted but Cj0046c in the cas9 mutant. This pseudogene was replaced 
by homologous recombination with a promoter-driven cjecas9 gene 
and an appropriate antibiotic gene for selection. WT and the genetic 
variant strains were cultured on blood agar plates containing 7% sheep 
blood (Becton Dickinson, Breda, The Netherlands) and the appropriate 
antibiotics (Sigma-Aldrich, Zwijndrecht, The Netherlands) for mutant 
and complemented mutant selection (table S3). Cultures were per-
formed under microaerophilic conditions at 37° using anaerobic jars 
and an Anoxomat (Mart Microbiology B.V., Drachten, The Netherlands). 
Infection experiments occurred at a multiplicity of infection (MOI) 
of 100 bacteria per one host cell, unless stated otherwise.
Maintenance of human cell lines
Human intestinal epithelial cell line Caco-2 (human epithelial 
colorectal adenocarcinoma cells), HeLa cells (human cervical cancer 
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cells), U2OS cells (human osteosarcoma cells), K562 (chronic 
myelogenous leukemia), and HEK293T cells (human embryonic 
kidney cells) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) [Thermo Fisher Scientific (TFS), Bleiswijk, The Netherlands] 
supplemented with 10% fetal bovine serum (FBS) (TFS, Bleiswijk, 
The Netherlands), penicillin (100 U/ml) (TFS, Bleiswijk, The Netherlands), 
streptomycin (100 g/ml) (TFS, Bleiswijk, The Netherlands), and 
1% nonessential amino acids (NEAA) (TFS, Bleiswijk, The Netherlands). 
The human cells were cultured in a 75-cm2 flask (Greiner Bio-One, 
Alphen aan den Rijn, The Netherlands) at 37°C and 5% CO2 in a 
humidified air incubator (Binder, Tuttlingen, Germany). All exper-
iments were performed with the U2OS cell line unless stated other-
wise. For example, HEK293T cells were used for technical reasons 
in experiments requiring a cancer cell line that adheres more loosely 
for more efficient cytoplasmic and nuclear fraction separations. To 
study the cell death induction, K562 suspension cells were used to 
prevent stress exposure by the trypsin/EDTA procedure that could 
affect the results obtained by the FACS analyses. All cell lines were 
ordered from the American Type Culture Collection for human cell 
lines and were routinely tested for mycoplasma.
Adhesion and invasion
The adherence and invasion of C. jejuni was determined by growing the 
U2OS cells to confluence at a final approximate density of 5.0 × 106 cells 
per well (Greiner Bio-One, Alphen aan den Rijn, The Netherlands). 
The adherence and invasion assays were performed by incubating 
the epithelial cells with C. jejuni at a ratio of 1:100. Bacteria and epithelial 
cells were coincubated for 20 min at 37°C under a 5% CO2 and 95% 
air atmosphere to assess adherence. For invasion, a subsequent 2-hour 
incubation of the epithelial cells was allowed. After incubation, 
monolayers were washed three times with prewarmed Hank’s balanced 
salt solution (HBSS) (TFS, Bleiswijk, The Netherlands). To sacrifice 
extracellular bacteria, monolayers were treated for 3 hours with a 
bactericidal concentration of gentamicin (480 g/ml; Sigma-Aldrich, 
Zwijndrecht, The Netherlands) in DMEM (TFS) containing 10% FBS 
(TFS) and 1% NEAA (TFS). After a wash, epithelial cells were lysed 
with 0.1% Triton X-100 (Cornell, Philadelphia, PA) in HBSS (TFS) 
for 15 min at room temperature. The number of C. jejuni bacteria 
that had invaded the cells was determined by plating serial dilutions 
of the lysis mix onto freshly prepared blood agar plates. After incu-
bation for 24 to 36 hours at 37°C in a microaerobic environment, 
colonies were counted and the colony-forming units per milliliter 
(CFU/ml) was calculated. For determination of adherence, cells were 
washed extensively three times with HBSS (TFS) after 15 to 20 min 
of incubation with the C. jejuni isolates. This time slot was sufficient 
to study adherence as reported (44). The cell monolayer was then 
detached with 0.1% Triton X-100 (Sigma-Aldrich), after which serial 
dilutions were plated onto Columbia blood agar plates (Becton 
Dickinson, Breda, The Netherlands). After incubation for 24 to 36 hours 
at 37°C in a microaerobic environment, colonies were counted, and 
the CFU/ml was calculated.
Cell death assay
Cells were seeded on six-well plates (Greiner Bio-One, Alphen aan den 
Rijn, The Netherlands) at a density of 1.0 × 105 cells per well and 
allowed to form a monolayer (U2OS, Caco-2, and HeLa cells). When 
the cells reached confluence, the medium was replaced with the 
maintenance medium without antibiotics. U2OS, Caco-2, HeLa, and 
K562 cells were infected at an MOI of 100 with WT, cas9, or cas9::cas9 
bacteria. Here, the infection process was followed over time using a 
phase contrast fluorescence microscope. At 24 to 120 hours after 
infection, pictures were taken to visualize deformation, detachment, 
and cell debris indicating cell stress or death. For the FACS analyses 
to assess apoptosis induction, K562 suspension cells were infected 
with WT, cas9, and the cas9::cas9 bacteria. Samples were collected 
at different time intervals (3 to 24 hours). Cells were then harvested 
for flow cytometry analysis (BD Accuri C6, BD Biosciences). To 
quantify the presence of dead cells, propidium iodide (PI; Sigma- 
Aldrich, Zwijndrecht, The Netherlands) staining was used according 
to the manufacturer’s protocol.
Isolation of C. jejuni OMVs
C. jejuni OMVs were isolated as described previously (16, 31). Briefly, 
overnight, C. jejuni cultures were centrifuged at 5000g for 30 min, 
and the resulting supernatant was filtered across a 0.22-m membrane 
(Corning, New York, USA). The filtrate was concentrated to 13 ml 
using an iCON Concentrator (TFS, Bleiswijk, The Netherlands) 20 
ml/9 K. The concentrated filtrate was ultracentrifuged at 150,000g 
for 3 hours at 4°C using a SW 41 Ti Rotor (Beckman Coulter, 
Woerden, The Netherlands). All isolation steps were carried out at 
4°C. The pellet was resuspended in phosphate-buffered saline (PBS) 
(TFS, Bleiswijk, The Netherlands) and stored at −80°C. OMV samples 
were pipetted onto blood agar plates containing 7% sheep blood 
(Becton Dickinson, Breda, The Netherlands) and incubated under 
both microaerophilic and (an)aerobic conditions for 48 hours to 
confirm the absence of viable bacteria. OMVs were quantified using 
the EVQuant (45).
Generation of C. jejuni bacteria expressing Cas9-mCherry 
fusion proteins
The C. jejuni Cas9-mCherry strains (table S3) were generated by overlap 
extension polymerase chain reaction (PCR) as described previously 
(46). Briefly, the primers that were used to amplify cas9-introduced 
overlapping ends for the mCherry gene (table S4). By using this 
overlap PCR method, we generated a single PCR product combin-
ing the individual PCR fragments for Cas9 and mCherry and a 
kanamycin resistance gene to allow for antibiotic selection. Then, the 
single Cas9-mCherry PCR product generated was introduced into 
the native cas9 locus of C. jejuni by electroporation to generate an 
mCherry-tagged Cas9 strain through homologous recombination.
In silico Cas9 protein sequence motif analyses
The Cas9 protein sequences from S. pyogenes M1-GAS (AAK33936.1), 
Staphylococcus aureus subsp. aureus (CCK74173.1), Listeria monocytogenes 
SLCC2482 (CBY05127.1), Francisella tularensis subsp. novicida U112 
(ABK89648.1), N. meningitidis 8013 (C9X1G5.1), Helicobacter cinaedi 
ATCCBAA-847 (YP_007601284.1), Campylobacter lari CF89-12 
(BAK69486.1), C. jejuni NCTC11168 (YP_002344900.1), and C. jejuni 
GB11 (5) were uploaded into the online MyHits motif scan software 
tool (http://myhits.isb-sib.ch/cgi-bin/motif_scan). The NLS motifs 
obtained were aligned using MUSCLE (www.ebi.ac.uk/Tools/msa/
muscle/), and the alignments were visualized and evaluated to identify 
amino acids with similar biochemical characteristics using MEGA6 
software (47).
Creation of expression clones for Cas9 proteins and NLS motifs
The coding sequences of the Cas9 proteins of C. jejuni and S. pyogenes 
or their NLS motifs were cloned into the pEGFP-C1 (Clontech, 
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Saint-Germain-en-Laye, France) vector for coexpression in eukaryotic 
cells. The pCDNA 3.1(+) vector (Invitrogen, Breda, The Netherlands) 
was used to express native C. jejuni or S. pyogenes Cas9 proteins in 
eukaryotic cells. The spycas9 or its catalytically inactive (“dead”) 
variant, spydcas9 gene, was cloned from the plasmids pMJ806 and 
pMJ841. These plasmids were provided by J. Doudna, University of 
California (UC) Berkeley, USA (30). Primers and plasmids used in 
this study are listed in tables S4 and S5, respectively. The presence of 
the CRISPR array and cas and cdt genes were analyzed by PCR using 
previously described methods (5, 44, 48). Genomic DNA were iso-
lated using a QIAamp DNA tissue stool kit (QIAGEN, Venlo, The 
Netherlands), and PCR amplification was performed using a Biomed 
Thermal Cycler System 9700 (TFS, Bleiswijk, The Netherlands). 
DNA digestion with restriction enzymes (New England Biolabs, 
Leiden, The Netherlands), ligation with a T4 DNA ligase (TFS, 
Bleiswijk, The Netherlands), purification, and agarose gel electro-
phoresis were performed according to the manufacturer’s protocols. 
Primer pairs and corresponding restriction enzymes used in this study 
are listed in table S4. The resulting constructs were electroporated 
at 2.5 kV, 200 ohm, and 25 F into Escherichia coli TOP10 cells 
(TFS, Bleiswijk, The Netherlands), resuspended in 37°C prewarmed 
super optimal broth with catabolite repression medium (TFS, Bleiswijk, 
The Netherlands), and allowed to recover with gentle shaking at 
37°C. After recovery, 100 l was plated onto a lysogeny broth (LB) 
(Becton Dickinson, Breda, The Netherlands) agar plate containing 
the appropriate selection marker (table S5). Positive colonies were 
cultured for plasmid DNA isolation (TFS, Bleiswijk, The Netherlands), 
and plasmids were sequenced using a BigDye Terminator sequencing 
kit (TFS, Bleiswijk, The Netherlands) and an ABI PRISM 3100 
Genetic Analyzer (TFS, Bleiswijk, The Netherlands), according to 
the manufacturer’s instructions.
Cas9 mutagenesis
A PCR-based site-directed mutagenesis method (46) was used to 
generate a catalytically inactive (dead) Cas9 (mutated D8A and 
H559A) or a NLS (BH) variant in CjeCas9 that was cloned into the 
pEGFP-C1 vector to obtain a GFP in-frame fusion protein at the 
C-terminal end of CjCas9. Primers are listed in table S4. Plasmids 
were transformed into chemically competent E. coli TOP10 cells 
(TFS, Bleiswijk, The Netherlands). After plasmid multiplication 
and isolation, the presence of the correct genetic mutations was 
confirmed by DNA sequencing.
Plasmid transfection
Human cells were seeded onto a two-well chamber slide (Sanbio, 
Uden, The Netherlands) at a density of 5.0 × 104 cells/ml. The next 
day, cells were transiently transfected with plasmid DNA using 
X-tremeGENE DNA Transfection Reagent (Roche Applied Science, 
Woerden, The Netherlands), according to the manufacturer’s 
protocols. After incubating at 37°C and 5% CO2 in a humidified 
incubator (Binder, Tuttlingen, Germany), the human cells were 
washed with prewarmed HBSS (TFS, Bleiswijk, The Netherlands) 
and fixed with 4% paraformaldehyde (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) for immunocytochemistry and microscopy, as 
described previously (44).
SDS-PAGE and Western blot analysis
C. jejuni bacteria or their OMVs were analyzed for the presence of 
CjeCas9 and CjeCas9-mCherry using SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) gel followed by Western blotting and stain-
ing with a C. jejuni anti-Cas9 antibody (5). Plasmid-transfected 
cells were washed with HBSS (TFS, Bleiswijk, The Netherlands), 
and cell lysates were prepared by adding Bond-Breaker TCEP solu-
tion (TFS, Bleiswijk, The Netherlands) in 2× Laemmli sample buffer 
(Bio-Rad, Veenendaal, The Netherlands) (1:9) before loading on a 
SDS-PAGE gel. Cellular lysates were then denatured at 95°C for 
5 min and immediately run through 4 to 20% Mini-PROTEAN 
TGX Precast Protein Gels (Bio-Rad, Veenendaal, The Netherlands). After 
electrophoresis, the proteins were blotted onto a polyvinylidene 
difluoride nitrocellulose membrane (Millipore, Amsterdam, The 
Netherlands). The membranes were blocked with PBS (TFS, 
Bleiswijk, The Netherlands) containing 5% nonfat dry milk (Bio-Rad, 
Veenendaal, The Netherlands) for 2 to 3 hours at room temperature 
or overnight at 4°C. For the detection of CjeCas9, SpyCas9, or their 
GFP-Cas9 fusion proteins, the membranes were incubated with primary 
polyclonal antibodies against CjeCas9 (5), monoclonal mouse anti- 
SpyCas9 (Abcam, Cambridge, UK), or rabbit polyclonal anti-GFP 
(NB600-308, Novus Biologicals, Abingdon, UK) at a dilution of 
1:1000 and incubated for 1.5 to 2 hours at room temperature. 
Appropriate secondary antibodies with alkaline phosphatase 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) were used at a dilution 
of 1:1000 to visualize the primary antibody binding using nitro blue 
tetrazolium/bromochloroindolyl phosphate (NBT/BCIP) solution 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) according to the 
manufacturer’s instructions. For cytoplasmic and nuclear protein 
fractions, NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(TFS, Bleiswijk, The Netherlands) were used, and proteins from 
eukaryotic cells were extracted according to the manufacturer’s 
instructions. Cytoplasmic and nuclear proteins were separated in a 
4 to 20% Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad, 
Veenendaal, The Netherlands). These were then Western blotted 
and incubated with one of the following: primary Cas9 antibodies, a 
mouse monoclonal anti–phospho-histone H2A.X (Ser139) clone JBW301 
(Millipore, Amsterdam, The Netherlands) at a 1:1000 dilution, or a 
mouse monoclonal anti–glyceraldehyde phosphate dehydrogenase 
(GAPDH) antibody (Abcam, Cambridge, UK) at a dilution of 1:5000. 
These steps were taken to detect the presence of Cas9 and the presence 
of DNA DSBs or to control for fraction quality and equal loading. 
Visualization was achieved with a NBT/BCIP solution (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) according to the manufacturer’s in-
structions. Quantification of the Western blot data occurred with 
the ImageJ software (49) using the analyzed gel option followed by 
surface plotting to analyze the pixel distribution on the Western 
blot. During these analyses, the background was set as white, and 
GAPDH, a house-keeping gene, was used as a loading control.
In vitro infection assays using glass chamber slides 
for microscopy
Cells were seeded onto two-well chamber slides (Greiner Bio-One, 
Alphen aan den Rijn) at a density of 1.5 × 105 cells per well and in-
cubated overnight at 37°C with 5% CO2 in a humidified incubator 
(Binder, Tuttlingen, Germany). Cells were exposed to NCTC11168, 
GB11, their derived genetic variants, or C. jejuni bacteria lacking 
CDT (cdt-). After overnight incubation at 37°C with 5% CO2 in a 
humidified air incubator (Binder, Tuttlingen, Germany), human 
cells were washed three times with prewarmed HBSS (TFS) at 37°C 
and fixed with 4% paraformaldehyde (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). Fixed cells were prepared for -H2AX or 53BP1 
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immunocytochemistry (see below) and/or (fluorescence) microscopy 
analyses, as described earlier (44).
Immunocytochemistry
For immunofluorescence detection, plasmid-transfected human cells 
were washed and fixed with 4% paraformaldehyde before permea-
bilization with 0.1% Triton X-100 (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). For -H2AX or 53BP1 antibody detection, human 
cells were incubated with a mouse anti–-H2AX antibody (Millipore, 
Amsterdam, The Netherlands) or rabbit polyclonal anti-53BP1 
(NB100-304, Novus Biologicals, Abingdon, UK) at a 1:1000 dilu-
tion. Secondary labeling and slide preparation were conducted as 
described previously (44). To visualize C. jejuni in human cells, an 
anti–C. jejuni fluorescein isothiocyanate–labeled antibody (Genway, 
San Diego, USA) was used. The nuclei of the eukaryotic cells were 
counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Labeling, 
detection of intracellular C. jejuni bacteria, and slide preparation 
were performed as previously described (44). Images were taken using 
a XI51 phase-contrast fluorescence microscope (Olympus, Leiden, 
The Netherlands) and further analyzed using Olympus cellSens or 
ImageJ/Fiji software (49). For 53BP1, more than 100 cells were ana-
lyzed in which the numbers of red 53BP1 foci per cell were counted. 
Then, the mean number of foci per cell was calculated per image 
taken by dividing the number of foci by the total number of human 
cells detected in the microscopic field. When we tested for the pres-
ence of -H2AX, more than 100 cells were analyzed for the presence 
of bright red nuclei. For cas9 exposed cells, even more indepen-
dent bright red foci were included as bright red nuclei and were 
enumerated. The percentage of bright red nuclei was calculated by 
counting the number of cells with bright red nuclei (based on our 
own criteria) and dividing them by the total number of cells in the 
same microscopic field, including cells without bright red nuclei, 
and then multiplying by 100.
Generation of heterologous plasmids for Cas9  
protein expression
For heterologous expression, the NCTC11168 cjeCas9 gene from 
the pEC-K-CBP-NTAP plasmid (donated by M. Jinek, University 
of Zurich, Switzerland) and the spyCas9 gene from the pET-28b-
Cas9-His plasmid [obtained from A. Schier (Addgene plasmid no. 
47327]) were PCR-amplified using Q5 DNA polymerase (New England 
Biolabs, Leiden, The Netherlands). We encountered serious tech-
nological difficulties when trying to express CjeCas9 of strain 
GB11 in E. coli. Therefore, we expressed CjeCas9 of C. jejuni strain 
NCTC11168 in E. coli. The amplified genes were inserted into the 
plasmid pML-1B (obtained from the UC Berkeley MacroLab, 
Addgene no. 29653) or pET28b backbone by NEBuilder HiFi DNA 
Assembly (New England Biolabs, Leiden, The Netherlands) using 
the oligonucleotides shown in table S4. This was done to generate a 
protein expression construct encoding the SpyCas9 or CjeCas9 
polypeptide sequence fused with a C-terminal (for SpyCas9) and an 
N-terminal tag (for CjeCas9) comprising a hexahistidine sequence 
and a tobacco etch virus (TEV) protease cleavage site. The assembly 
mix was used to transform the competent E. coli DH5 strain (New 
England Biolabs, Leiden, The Netherlands). The plasmids were iso-
lated and verified by Sanger sequencing (Macrogen, Amsterdam, 
The Netherlands) before transforming the E. coli Rosetta 2 (DE3) 
strain. The plasmids containing the WT genes were used as PCR 
templates to generate active site mutants of SpyCas9 and CjeCas9 
via site-directed mutagenesis. In SpyCas9, D10A, H840A, and D10A- 
H840A amino acid substitutions yielded a RuvC, HNH, and double 
mutant, respectively. In NCTC11168 CjeCas9, D8A, H559A, and 
D8A-H559A amino acid substitutions yielded a RuvC, HNH, and 
double mutant, respectively. All bacterial expression plasmids used 
in this study can be found in table S5.
Cas9 expression and purification
Purification protocols were adapted from previously established 
Cas12a purification methods (50). The NCTC11168 cjecas9 and 
spycas9 genes were heterologous expressed in E. coli and purified 
using a combination of Ni2+ affinity, cation exchange, and gel filtra-
tion chromatography steps. Three liters of LB growth medium with 
ampicillin (100 g/ml) were inoculated with 30 ml of overnight culture 
of Rosetta cells (DE3) (EMD Millipore, Ontario, Canada) contain-
ing the expression constructs. Cultures were grown to an optical 
density at 600 nm (OD600nm) of 0.5 to 0.6. Expression was induced 
by adding isopropyl -d-1-thiogalactopyranoside to a final concen-
tration of 0.2 mM, and incubation was continued overnight at 
18°C. Cells were harvested by centrifugation, and the cell pellet was 
resuspended in 50 ml of lysis buffer [20 mM tris-HCl (pH 8), 500 mM 
NaCl, and 5 mM imidazole supplemented with protease inhibitors 
(Roche, Woerden, The Netherlands)]. Cells were lysed by sonication, 
and the lysates were centrifuged for 45 min at 4°C at 30,000g to 
remove insoluble material. The cleared lysate was applied to a 5-ml 
HisTrap HP column (GE Healthcare, Eindhoven, The Netherlands). 
The column was washed with 10 column volumes of wash buffer 
[20 mM tris-HCl (pH 8), 250 mM NaCl, and 20 mM imidazole], 
and the bound proteins were eluted in elution buffer [20 mM 
tris-HCl (pH 8), 250 mM NaCl, and 250 mM imidazole]. Fractions con-
taining pure proteins were pooled, and TEV protease was added in 
a 1:100 (w/w) ratio. The sample was dialyzed against a dialysis buffer 
[20 mM Hepes-KOH (pH 7.5) and 250 mM KCl] at 4°C overnight. 
For further purification, the protein was diluted 1:1 with 10 mM 
Hepes-KOH (pH 7.5) and loaded on a HisTrap Heparin HP column 
(GE Healthcare, Eindhoven, The Netherlands). The column was 
washed with ion exchange chromatography (IEX) buffer A [20 mM 
Hepes-KOH (pH 7.5) and 150 mM KCl] and eluted with IEX buffer 
B [20 mM Hepes-KOH (pH 7.5) and 2 M KCl] by applying a gradient 
from 0 to 50% over a total volume of 60 ml. Peak fractions were 
analyzed by SDS-PAGE, and fractions containing the Cas9 protein were 
combined. Then, dithiothreitol (DTT; Sigma-Aldrich, Zwijndrecht, 
The Netherlands) was added to a final concentration of 1 mM. The 
protein was fractionated on a HiLoad 16/600 Superdex 200 gel filtration 
column (GE Healthcare, Eindhoven, The Netherlands) and eluted 
with size exclusion chromatography (SEC) buffer [20 mM Hepes-
KOH (pH 7.5), 500 mM KCl, and 1 mM DTT). Peak fractions were 
combined, concentrated to 10 mg/ml, flash frozen in liquid nitrogen, 
and either used directly for biochemical assays or stored frozen at 
−80°C for future use.
GFP expression and FACS analysis
For genome editing and FACS analyses, we used the K562(GFPmut) 
cell line (42), which was seeded into a 24-well plate (Greiner Bio-One, 
Alphen aan den Rijn, The Netherlands). Cells were then recovered 
overnight at 37°C at 5% CO2 in a humidified air incubator (Binder, 
Tuttlingen, Germany). We then transfected the K562(GFPmut) cells 
(TFS, Bleiswijk, The Netherlands) with a CRISPR ribonucleoprotein 
(RNP) complex consisting of bacterial NCTC11168 CjeCas9 or 
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SpyCas9 (New England Biolabs, Leiden, The Netherlands) and a 
synthetic guide RNA (Biolegio, Nijmegen, The Netherlands) using 
Lipofectamine 2000 (TFS, Bleiswijk, the Netherlands). In addition, 
a PCR product generated from the GFP gene was transfected at the 
same time. Production of active RNP complexes and lipofection 
were carried out according to the manufacturer’s protocols. The 
synthetic guide RNA sequence for SpyCas9 (gRNA_AAVS1-T2) was 
described earlier (42), and the guide for CjeCas9 single guide RNA 
is listed in table S5. Seventy-two hours after transfection, the 
K562(GFPmut) cells were harvested using ice-cold HBSS (TFS, 
Bleiswijk, The Netherlands) and kept on ice. After the second wash, 
the cells were resuspended in 0.4 ml of HBSS (TFS) containing PI 
from an apoptosis detection kit (GeneCopoeia, Rockville, USA). 
After 20 min, the K562(GFPmut) cells were analyzed using FACS 
(BD Accuri C6) and BD Accuri C6 Software (version 8.8.6).
DNA DSB detection using BLESS
U2OS cells were seeded into 75-cm2 flasks (±1 to 5 million cells) 
(Greiner Bio-One, Bleiswijk, The Netherlands) and allowed to grow 
to confluence at 37°C at 5% CO2 in a humidified air incubator 
(Binder, Tuttlingen, Germany). Cells were infected with GB11, 
GB11cas9, or GB11cas9::cas9 bacteria in a humidified air incu-
bator (Binder, Tuttlingen, Germany) at 37°C and 5% CO2. After 
6 hours, samples were fixed and prepared for sequencing according 
to the BLESS protocol (32) to obtain a snapshot of induced DSBs. 
This procedure was repeated for plasmid-transfected cells, which 
were harvested and processed for sequencing after 24 or 48 hours, 
respectively. As a positive control for DSB induction, a U2OS cell 
line harboring a stably integrated genomic I–Sce I restriction site 
was used according to the original BLESS protocol (32). In addition, 
gamma () irradiation was applied for random induction of DSBs. 
U2OS cells received 1 gray (Gy) of 137Cs  radiation at a dose rate of 
0.6 Gy min−1. After irradiation, cells were allowed to recover for 
30 min at 37°C with 5% CO2 in a humidified air incubator (Binder, 
Tuttlingen, Germany) and further processed according to the orig-
inal BLESS protocol. Paired-end sequencing of samples with Illumi-
na HiSeq2500 v4 was performed by an accredited service provider 
(ServiceXS, Leiden, The Netherlands), according to the manufac-
turer’s protocol (Illumina). The resulting FASTQ files were demul-
tiplexed, and 75–base pair–sized genomic sequence fragments 
including the BLESS primers (32) and sequencing barcodes were 
removed. The resulting FASTQ files were mapped as paired reads 
per sample using Burrows-Wheeler Alignment Maximal Exact 
Matches (BWA MEM) (version 0.7.12.1) against the GRCh37/hg19 
human genome assembly. Duplicate reads were flagged using 
Picard MarkDuplicates (version 1.136.0), and high-quality dupli-
cate reads with a mapping quality score of >30 were selected using 
SAMtools (version 1.19). The forward read from these sequences, 
including genomic location, were stored as ASCII files. The fre-
quency of reads at the same genomic location was determined for 
each sample, and only those positions for which four reads or more 
were mapped to DSBs were selected for further analysis. The fre-
quency results from the experimental control sample were used to 
filter nonspecific DSBs from all other test samples based on genomic 
location. Reads associated with positive DSBs were visualized using 
the Integrated Genome Viewer (version 2.3), and a summary of the 
breakpoint comparisons was visualized as circos plots generated us-
ing the R (version 3.1.1) circlize package (https://cran.r-project.org/
web/packages/circlize/index.html, version 0.3.8).
PAM motif identification
The identified DSB positions on the GRCh37/hg19 genome obtained 
by BLESS were used to extract nucleotides upstream and downstream 
of DSB positions using the Fetch software tool and the extract genomic 
DNA feature using coordinates from assembled/unassembled genomes 
that are available in Galaxy version 2.2.4 (http://usegalaxy.org). The 
extracted sequences, 10 bases upstream or downstream of the cleavage 
site obtained from the raw and filtered BLESS datasets, were analyzed 
from 5′ to 3′ and from 3′ to 5′ for the presence of a potential PAM 
motif. This was accomplished using WebLogo (http://weblogo.
berkeley.edu/logo.cgi) or manually in Excel (Microsoft) using fre-
quency counting of the nucleotides A, T, C, G at each individual 
position upstream or downstream of the break position using text 
filter options. This was done because the BLESS technique can 
sometimes result in the filling or removal of overhanging nucleotides 
at the DSB position that can then change the potential PAM position 
(32). The extracted sequences were further analyzed.
In vitro Cas9 U2OS genomic DNA digestion assays
Genomic DNA cleavage assays were performed in a final volume of 
30 l with 300 ng of DNA isolated from the U2OS cell line. DNA 
was isolated from cultured cells using a DNeasy blood and tissue kit 
(QIAGEN, Venlo, The Netherlands), then treated with ribonuclease 
A (Promega Benelux B.V., Leiden, The Netherlands), and purified. 
A total of 30 pmol of NCTC11168 CjeCas9 and SpyCas9 proteins 
(final concentration of 1 M) were used for cleavage reaction with 
or without different metal ions (Mg2+/Mn2+) in the cleavage buffer 
[20 mM Hepes (pH 7.5), 150 mM KCl, 0.5 mM DTT, and 0.1 mM 
EDTA) and incubated at 37°C for 1, 6, and 24 hours. Different re-
striction enzymes (New England Biolabs, Leiden, The Netherlands) 
were used with their appropriate buffer as controls. The reactions 
were stopped by adding proteinase K and 6× DNA loading dye, purple 
(New England Biolabs, Leiden, The Netherlands). The genomic DNA 
was resolved on an agarose gel (0.8%) or denaturing urea-agarose gel 
(1%) stained with SYBR Gold Nucleic Acid Gel Stain (TFS, Bleiswijk, 
The Netherlands) and visualized using a Amersham Typhoon Gel 
and Blot Imaging Systems (GE Healthcare, Eindhoven, The Netherlands). 
To denature genomic DNA, the reactions were stopped at indicated 
time points by adding 40 l of denaturing sample buffer containing 
8 M urea and 0.3% SDS. Samples were denatured by incubating them 
for 10 min at 85°C and loading them directly on a 1% urea (2 M) 
agarose gel in tris-acetate-EDTA buffer as described (51).
Plasmid cleavage assay
Plasmid cleavage assays were performed in a final volume of 20 l 
with 6 nM plasmid DNA (pUC19) and 100 nM CjeCas9 (NCTC11168) 
or SpyCas9 nucleases in the presence of 10 mM EDTA or 5 mM 
either MgCl2 or MnCl2 at 37°C for 1 hour. Other metal salts were 
tested but did not show any activation of the CjeCas9 (NCTC11168) 
or SpyCas9 nucleases. As a control, the reaction was performed 
without any added metal or EDTA to account for any fortuitous 
metal associated with the protein preparation. The reactions were 
stopped by adding 10 mM EDTA and 1% SDS, after which 6× DNA 
loading dye (New England Biolabs, Leiden, The Netherlands) was 
added. The DNA was resolved on an agarose gel (0.8%) stained with 
SYBR Safe DNA Gel Stain (TFS, Bleiswijk, The Netherlands) and 
visualized using a G:BOX F3 gel imager (Syngene, Bangalore, India). 
To create DNA mobility standards, pUC19 was separately treated 
with a linearizing enzyme Eco RI (New England Biolabs, Leiden, 
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The Netherlands) or the nicking enzyme Nt. Bsp QI (New England 
Biolabs, Leiden, The Netherlands). Both Eco RI and Nt. Bsp QI have 
a single recognition site in the pUC19 plasmid.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/25/eaaz4849/DC1
View/request a protocol for this paper from Bio-protocol.
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